ISAL 2019 | Off-the-shelf CAR-T for T-cell malignancies: UCART3
While CAR T-cells are shaking-up the treatment paradigm, off-the-shelf CAR T-cells are moving up the pipeline. We spoke to John DiPersio, MD, PhD, of Washington University School of Medicine, Washington, WA, about this at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. Prof. DiPersio discusses UCART3, a self-purifying, fracticide and GvHD resistant off-the-shelf CAR-T, which targets CD3 and is currently under Phase III investigation for T-cell malignancies.
Get great new content delivered to your inboxSign up